SCHEMBL7557641

SCHEMBL7557641

COc1ccc2c(c1)c(/C=C1/SC(=O)NC1=O)cn2-c1ccc(/C=C2/SC(=O)NC2=O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.73
PIM1 P11309 4/20 0.58
PIM2 Q9P1W9 4/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
AKR1B1 P15121 2/20 0.58
ATM Q13315 1/20 0.55
PTGS2 P35354 2/20 0.51
HPGD P15428 1/20 0.49
MGAM O43451 1/20 0.49
GAA P10253 1/20 0.49
SI P14410 1/20 0.49
MGAM2 Q2M2H8 1/20 0.49
POLB P06746 1/20 0.48
CSNK2A2 P19784 1/20 0.48
CLK1 P49759 1/20 0.48
CSNK2B P67870 1/20 0.48
CSNK2A1 P68400 1/20 0.48
DYRK1A Q13627 1/20 0.48
DYRK1B Q9Y463 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7557646 1.00 GSK3B (0.73) GSK3BPIM1PIM2NPC1RAB9A
SCHEMBL7557100 0.83 PTPN1 (0.64) GSK3BPTGS2HPGDPOLB
SCHEMBL7557105 0.83 PTPN1 (0.64) GSK3BPTGS2HPGDPOLB
SCHEMBL1247708 0.76 PIM1 (1.00) GSK3BPIM1PIM2NPC1RAB9A
SCHEMBL2546911 0.76 PIM1 (1.00) GSK3BPIM1PIM2NPC1RAB9A
SCHEMBL1247705 0.76 PIM1 (1.00) GSK3BPIM1PIM2NPC1RAB9A
SCHEMBL30379318 0.75 PARP1 (0.57) PIM1PIM2AKR1B1MGAMGAA
SCHEMBL20603194 0.75 PARP1 (0.57) PIM1PIM2AKR1B1MGAMGAA
SCHEMBL20603192 0.75 PARP1 (0.57) PIM1PIM2AKR1B1MGAMGAA
SCHEMBL7554801 0.75 GSK3B (0.63) GSK3BPIM1PIM2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020115700-A1 Substituted indole compounds and methods of their use CHIN ALLISON C (US) 2002-08-22 US disclosed
US-6372742-B1 TELOMERASE ENZYME INHIBITORS AND ANTICANCER AGENTS GERON CORPORATION 2002-04-16 US disclosed
EP-1109808-A1 SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER Geron Corporation (US) 2001-06-27 EP disclosed
WO-2001002394-A1 SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER GERON CORPORATION (US) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115700-A1 Substituted indole compounds and methods of their use TERT, INMT, POT1 GSK3B 451/4885PIM1 310/4885PIM2 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.